相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
May Daher et al.
BLOOD (2021)
A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells
Upasana Sunil Arvindam et al.
LEUKEMIA (2021)
Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
Malin S. Nilsson et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
Phase I study of cellular therapy using ex vivo expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients
Junji Tanaka et al.
HAEMATOLOGICA (2020)
Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
Huang Zhu et al.
BLOOD (2020)
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia
Rupa Narayan et al.
CANCER (2020)
Essential role of TNF-α in gamma c cytokine aided crosstalk between dendritic cells and natural killer cells in experimental murine lymphoma
Uttam Gupta et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Cord blood stem cell derived CD16+ NK cells eradicated acute lymphoblastic leukemia cells using with anti-CD47 antibody
Behnaz Valipour et al.
LIFE SCIENCES (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia
Mario Munoz Builes et al.
BMJ OPEN (2020)
Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane -bound interleukin-21 expanded natural killer cells in acute myeloid leukemia
Rajeswaran Mani et al.
CYTOTHERAPY (2020)
Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo
Xiang-Yu Zhao et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2020)
IL-27 impact on NK cells activity: Implication for a robust anti-tumor response in chronic lymphocytic leukemia
Maral Hemati et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
NK Cell-Based Immune Checkpoint Inhibition
Muhammad Khan et al.
FRONTIERS IN IMMUNOLOGY (2020)
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas
Margery Gang et al.
BLOOD (2020)
Treating acute myeloid leukemia in the modern era: A primer
William G. Blum et al.
CANCER (2020)
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
Aaron D. Goldberg et al.
LEUKEMIA RESEARCH (2020)
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents
Carsten Riether et al.
NATURE MEDICINE (2020)
Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies
Keerthana Shankar et al.
STEM CELL RESEARCH & THERAPY (2020)
Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
Melissa M. Berrien-Elliott et al.
CANCER DISCOVERY (2020)
An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia
Bing Zheng et al.
CLINICAL CANCER RESEARCH (2019)
Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation
Awais Ijaz et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Ouabain promotes immune responses in WEHI-3 cells to generate leukemia mice through enhancing phagocytosis and natural killer cell activities in vivo
Yung-Luen Shih et al.
ENVIRONMENTAL TOXICOLOGY (2019)
Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based Off-the-Shelf Acute Myeloid Leukemia Immunotherapies
Stephan Kloess et al.
HUMAN GENE THERAPY (2019)
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma
Maria Cuce et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia
Rosa Nguyen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies
Yingxi Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
Melanie Maerklin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?
Brian Ball et al.
HAEMATOLOGICA (2019)
Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
Katherine D. Cummins et al.
HAEMATOLOGICA (2019)
High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations
Barbora Brodska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation
Daniela Pende et al.
FRONTIERS IN IMMUNOLOGY (2019)
Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
Weilei Hu et al.
FRONTIERS IN IMMUNOLOGY (2019)
Recent drug approvals for acute myeloid leukemia
Catherine Lai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
Farhad Ravandi et al.
LANCET HAEMATOLOGY (2019)
Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after Hematopoietic Cell Transplantation
Jeffrey J. Bednarski et al.
BLOOD (2019)
Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease
Sabine Kayser et al.
BLOOD (2019)
Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT)
Jennifer A. Foltz et al.
BLOOD (2019)
Casticin Promotes Immune Responses, Enhances Macrophage and NK Cell Activities, and Increases Survival Rates of Leukemia BALB/c Mice
Kuang-Chi Lai et al.
AMERICAN JOURNAL OF CHINESE MEDICINE (2019)
Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
Norimichi Hattori et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
David A. Sallman et al.
BLOOD (2019)
Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo plus Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
Naval G. Daver et al.
BLOOD (2019)
Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Uma Borate et al.
BLOOD (2019)
Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
Joshua F. Zeidner et al.
BLOOD (2019)
Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1
Daniel Ernst et al.
BLOOD CANCER JOURNAL (2019)
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Naval Daver et al.
CANCER DISCOVERY (2019)
NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia
Ming-Chin Chang et al.
FRONTIERS IN IMMUNOLOGY (2019)
Acute myeloid leukemia and NK cells: two warriors confront each other
Aroa Baragano Raneros et al.
ONCOIMMUNOLOGY (2019)
Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody
Bastian J. Schmied et al.
CANCERS (2019)
First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia
Sarah Cooley et al.
BLOOD ADVANCES (2019)
Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia
Hyun Don Yun et al.
BLOOD ADVANCES (2019)
CAR T Cell Toxicity: Current Management and Future Directions
Lucrecia Yanez et al.
HEMASPHERE (2019)
Preclinical Targeting of Human Acute Myeloid Leukemia Using CD4-specific Chimeric Antigen Receptor (CAR) T Cells and NK Cells
Huda Salman et al.
JOURNAL OF CANCER (2019)
Characterization of SGN-CD123A, APotent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia
Fu Li et al.
MOLECULAR CANCER THERAPEUTICS (2018)
A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia
Todd A. Fehniger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Rizwan Romee et al.
BLOOD (2018)
Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia
M. Vela et al.
CANCER LETTERS (2018)
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
Ye Li et al.
CELL STEM CELL (2018)
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
Andreas T. Bjorklund et al.
CLINICAL CANCER RESEARCH (2018)
CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice
Brent A. Williams et al.
HAEMATOLOGICA (2018)
A Developed NK-92MI Cell Line with Siglec-7neg Phenotype Exhibits High and Sustainable
Chin-Han Huang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
Naval Daver et al.
LEUKEMIA (2018)
IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML
Yelena Kovtun et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Metabolism of an Oxime-Linked Antibody Drug Conjugate, AGS62P1, and Characterization of Its Identified Metabolite
Josh T. Snyder et al.
MOLECULAR PHARMACEUTICS (2018)
Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models
Folashade Otegbeye et al.
PLOS ONE (2018)
CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice
Brent A. Williams et al.
HAEMATOLOGICA (2018)
CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells
Jens H. W. Pahl et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities
Aude Le Roy et al.
FRONTIERS IN IMMUNOLOGY (2018)
Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.
Tapan M. Kadia et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia
Monica Villa-Alvarez et al.
FRONTIERS IN IMMUNOLOGY (2018)
IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice
Yimin Shi et al.
BLOOD ADVANCES (2018)
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Katherine E. Lindblad et al.
BLOOD (2018)
Targeted Conditioning of Iomab-B (131I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial
Edward Agura et al.
BLOOD (2018)
A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies
Naval G. Daver et al.
BLOOD (2018)
Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy
Sara Mastaglio et al.
BLOOD ADVANCES (2018)
Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells
Veronika Bachanova et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHD
Yuen Ling Tracey Chan et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2018)
CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia
Ying-Ping Jiang et al.
BLOOD ADVANCES (2018)
Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy
Yuan Hu et al.
ACTA PHARMACOLOGICA SINICA (2018)
Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice
Jeannette Cany et al.
BLOOD (2018)
An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia
S. P. Koerner et al.
LEUKEMIA (2017)
Recent developments in immunotherapy of acute myeloid leukemia
Felix S. Lichtenegger et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Immunotherapy in hematologic malignancies: past, present, and future
Annie Im et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
NK cell-based immunotherapy for cancer
Fang Fang et al.
SEMINARS IN IMMUNOLOGY (2017)
Mechanisms of Immune Tolerance in Leukemia and Lymphoma
Emily K. Curran et al.
TRENDS IN IMMUNOLOGY (2017)
Programmed differentiated natural killer cells kill leukemia cells by engaging SLAM family receptors
Yang Wu et al.
ONCOTARGET (2017)
Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition
Aroa Baragano Raneros et al.
ONCOTARGET (2017)
Targeting CD157 in AML using a novel, Fc-engineered antibody construct
Christina Krupka et al.
ONCOTARGET (2017)
Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia
Anne-Sophie Chretien et al.
FRONTIERS IN IMMUNOLOGY (2017)
In Vitro culture with interleukin-15 leads to expression of activating receptors and recovery of natural Killer cell Function in acute Myeloid Leukemia Patients
Beatriz Sanchez-Correa et al.
FRONTIERS IN IMMUNOLOGY (2017)
Phase 1 clinical trial of adoptive immunotherapy using off-the-shelf activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia
Michael Boyiadzis et al.
CYTOTHERAPY (2017)
Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation
Stefan O. Ciurea et al.
BLOOD (2017)
Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients
Harry Dolstra et al.
CLINICAL CANCER RESEARCH (2017)
Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation
F-X Gros et al.
BONE MARROW TRANSPLANTATION (2017)
NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy
Garnet Suck et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
Loredana Ruggeri et al.
HAEMATOLOGICA (2016)
CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT
F. Cichocki et al.
LEUKEMIA (2016)
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
Loredana Ruggeri et al.
HAEMATOLOGICA (2016)
Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia
Anna Martner et al.
ONCOIMMUNOLOGY (2016)
Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia
Daniela Sandoval-Borrego et al.
ARCHIVES OF MEDICAL RESEARCH (2016)
Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation
Brian C. Shaffer et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial
Dean A. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia
Inpyo Choi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts
Sumithira Vasu et al.
BLOOD (2016)
Exploitation of natural killer cells for the treatment of acute leukemia
Rupert Handgretinger et al.
BLOOD (2016)
Cancer immunotherapy: the beginning of the end of cancer?
Sofia Farkona et al.
BMC MEDICINE (2016)
Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients
Antonio Curti et al.
CLINICAL CANCER RESEARCH (2016)
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Daniel A. Vallera et al.
CLINICAL CANCER RESEARCH (2016)
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
Sergio Amadori et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Matthew S. Davids et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
An overview of the potential strategies for NK cell-based immunotherapy for acute myeloid leukemia
Chandrima Sinha et al.
PEDIATRIC BLOOD & CANCER (2016)
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
Rizwan Romee et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation
Angelica Cuapio et al.
ONCOTARGET (2016)
NK-DC Crosstalk in Immunity to Microbial Infection
Rony Thomas et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2016)
Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia
Maulik Vyas et al.
ONCOIMMUNOLOGY (2016)
Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing
Conor J. Kearney et al.
ONCOIMMUNOLOGY (2016)
Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML
Ju Huang et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2016)
Novel Immunotherapies for Hematological Malignancies
Monali Vasekar et al.
CURRENT MOLECULAR PHARMACOLOGY (2016)
Generation of Highly Cytotoxic Natural Killer Cells for Treatment of Acute Myelogenous Leukemia Using a Feeder-Free, Particle-Based Approach
Jeremiah L. Oyer et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Generation and Preclinical Characterization of an NKp80-Fc Fusion Protein for Redirected Cytolysis of Natural Killer (NK) Cells against Leukemia
Gang Deng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
Daniel S. Pereira et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Cancer immunotherapy: Strategies for personalization and combinatorial approaches
Vishwanath Sathyanarayanan et al.
MOLECULAR ONCOLOGY (2015)
Natural killer cell therapy in children with relapsed leukemia
Jeffrey E. Rubnitz et al.
PEDIATRIC BLOOD & CANCER (2015)
Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia
Helena Agerstam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance
Anna Martner et al.
ONCOTARGET (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia
A. Baragano Raneros et al.
GENES AND IMMUNITY (2015)
Memory-like responses of natural killer cells
Megan A. Cooper et al.
IMMUNOLOGICAL REVIEWS (2015)
An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia
Julia Steinbacher et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia
Simon Z. He et al.
LEUKEMIA & LYMPHOMA (2015)
Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial
Panagiotis D. Kottaridis et al.
PLOS ONE (2015)
MEN1112/OBT357, an Anti Bst1/CD157 Humanized Antibody Inducing Acute Myelogenous Leukemia (AML) Blast Depletion in an Autologous Ex Vivo Assay: A Potential New Targeted Therapy for AML
Adriano Venditti et al.
BLOOD (2015)
Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study
Inpyo Choi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein
Veronika Bachanova et al.
BLOOD (2014)
Restoration of natural killer cell cytotoxicity by VEGFR-3 inhibition in myelogenous leukemia
Ji Yoon Lee et al.
CANCER LETTERS (2014)
Early lymphocyte recovery at 28 d post-transplant is predictive of reduced risk of relapse in patients with acute myeloid leukemia transplanted with peripheral blood stem cell grafts
Fotios V. Michelis et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Effect of tumor cells and tumor microenvironment on NK-cell function
Massimo Vitale et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia
Kate Stringaris et al.
HAEMATOLOGICA (2014)
hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo
Wen Jiang et al.
IMMUNOBIOLOGY (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
Are natural killer cells superior CAR drivers?
Hans Klingemann
ONCOIMMUNOLOGY (2014)
Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers
M. Stern et al.
BONE MARROW TRANSPLANTATION (2013)
Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib
Izuru Mizoguchi et al.
CANCER SCIENCE (2013)
NK cell-based immunotherapy for malignant diseases
Min Cheng et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2013)
Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
Andres Wiernik et al.
CLINICAL CANCER RESEARCH (2013)
Safrole Suppresses Murine Myelomonocytic Leukemia WEHI-3 Cells In Vivo, and Stimulates Macrophage Phagocytosis and Natural Killer Cell Cytotoxicity in Leukemic Mice
Fu-Shun Yu et al.
ENVIRONMENTAL TOXICOLOGY (2013)
Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia
Mikkael A. Sekeres et al.
HAEMATOLOGICA (2013)
Natural killer cell biology: An update and future directions
Kerry S. Campbell et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
A VEGFR-3 Antagonist Increases IFN-γ Expression on Low Functioning NK Cells in Acute Myeloid Leukemia
Ji Yoon Lee et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2013)
Receptor Activator for NF-κB Ligand in Acute Myeloid Leukemia: Expression, Function, and Modulation of NK Cell Immunosurveillance
Benjamin Joachim Schmiedel et al.
JOURNAL OF IMMUNOLOGY (2013)
IL-15 Improves the Cytotoxicity of Cytokine-induced Killer Cells Against Leukemia Cells by Upregulating CD3+CD56+ Cells and Downregulating Regulatory T Cells As Well As IL-35
Qianshan Tao et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Generation and Preclinical Characterization of a Fc-optimized GITR-Ig Fusion Protein for Induction of NK Cell Reactivity Against Leukemia
Benjamin Joachim Schmiedel et al.
MOLECULAR THERAPY (2013)
Natural Killer Cells Generated from Cord Blood Hematopoietic Progenitor Cells Efficiently Target Bone Marrow-Residing Human Leukemia Cells in NOD/SCID/IL2Rgnull Mice
Jeannette Cany et al.
PLOS ONE (2013)
Innate lymphoid cells - a proposal for uniform nomenclature
Hergen Spits et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Repeated Dosing Of Anti-KIR (IPH2101) As Maintenance Therapy In Ederly Patients With Acute Myeloid Leukemia
Norbert Vey et al.
BLOOD (2013)
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Norbert Vey et al.
BLOOD (2012)
Cytokine activation induces human memory-like NK cells
Rizwan Romee et al.
BLOOD (2012)
Antibody-Dependent Cell-Mediated Cytotoxicity Overcomes NK Cell Resistance in MLL-Rearranged Leukemia Expressing Inhibitory KIR Ligands but Not Activating Ligands
Wing Keung Chan et al.
CLINICAL CANCER RESEARCH (2012)
Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients
Beatriz Sanchez-Correa et al.
IMMUNOLOGY AND CELL BIOLOGY (2012)
Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses
Julia Hilpert et al.
JOURNAL OF IMMUNOLOGY (2012)
Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
Michelle K. Gleason et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
Natural killer cell immune escape in acute myeloid leukemia
E. Lion et al.
LEUKEMIA (2012)
Macrophages Help NK Cells to Attack Tumor Cells by Stimulatory NKG2D Ligand but Protect Themselves from NK Killing by Inhibitory Ligand Qa-1
Zhixia Zhou et al.
PLOS ONE (2012)
Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models
Eva Rettinger et al.
FRONTIERS IN ONCOLOGY (2012)
Induction of PD-1 and PD-1 Ligand Expression by Hypomethylating Agents (HMA) in Myelodysplastic Syndromes and Acute Myelogenous Leukemia Suggest a Role for T Cell Function in Clinical Resistance to Hmas
Hui Yang et al.
BLOOD (2012)
Pre-eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission
Nicolas Dauguet et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
Antonio Curti et al.
BLOOD (2011)
CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia
S. J. Coles et al.
LEUKEMIA (2011)
Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process
Jan Spanholtz et al.
PLOS ONE (2011)
Natural Killer Cell Killing of Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia Blasts by Killer Cell Immunoglobulin-Like Receptor-Negative Natural Killer Cells after NKG2A and LIR-1 Blockade
Robert Godal et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Donor KIR Genes 2DL5A, 2DSI and 3DSI Are Associated with a Reduced Rate of Leukemia Relapse After HLA-Identical Sibling Stem Cell Transplantation for Acute Myeloid Leukemia but Not Other Hematologic Malignancies
Kate Stringaris et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells
Tina Baessler et al.
BLOOD (2010)
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia
Sarah Cooley et al.
BLOOD (2010)
Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients
G. Pittari et al.
BONE MARROW TRANSPLANTATION (2010)
Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study
S. R. Yoon et al.
BONE MARROW TRANSPLANTATION (2010)
A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting
Markus Kuegler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors
Miroslaw J. Szczepanski et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis
Xuzhang Lu et al.
CANCER SCIENCE (2010)
Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: Comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression
Veronique Decot et al.
EXPERIMENTAL HEMATOLOGY (2010)
NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia
Jeffrey E. Rubnitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study
Cecile Pautas et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16
Heiko Singer et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Glucocorticoid-Induced Tumor Necrosis Factor Receptor-Related Protein Ligand Subverts Immunosurveillance of Acute Myeloid Leukemia in Humans
Tina Baessler et al.
CANCER RESEARCH (2009)
Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate
A. Poggi et al.
LEUKEMIA (2009)
Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720
Maria R. Baer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
NK cells and cancer immunosurveillance
I. Waldhauer et al.
ONCOGENE (2008)
Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group
Beverly J. Lange et al.
BLOOD (2008)
NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities
Stefan Diermayr et al.
BLOOD (2008)
Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia
B. N. Savani et al.
LEUKEMIA (2007)
Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis
Andreas Rohner et al.
LEUKEMIA RESEARCH (2007)
Donor natural killer cell allorecognition of missing self in haploidentical hernatopoietic transplantation for acute myeloid leukemia: challenging its predictive value
Loredana Ruggeri et al.
BLOOD (2007)
Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT
Jeffery S. Miller et al.
BLOOD (2007)
Expression of the target receptor CD33 in CD34(+)/CD38(-)/CD123(+) AML stem cells
A. W. Hauswirth et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2007)
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
A-L Taksin et al.
LEUKEMIA (2007)
In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection
Yan Zhang et al.
IMMUNOLOGY (2007)
Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction
Cyril Fauriat et al.
BLOOD (2007)
Human NK cell education by inhibitory receptors for MHC class I
Nicolas Anfossi et al.
IMMUNITY (2006)
Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial
Mats Brune et al.
BLOOD (2006)
Licensing of natural killer cells by host major histocompatibility complex class I molecules
S Kim et al.
NATURE (2005)
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia
EJ Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Natural killer cell alloreactivity for leukemia therapy
L Ruggeri et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias
P Nowbakht et al.
BLOOD (2005)
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
JS Miller et al.
BLOOD (2005)
Specific targeting of CD33+ leukemia cells by a natural killer cell line modified with a chimeric receptor
T Schirrmann et al.
LEUKEMIA RESEARCH (2005)
Activation of NK cell cytotoxicity
MJ Smyth et al.
MOLECULAR IMMUNOLOGY (2005)
Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia
H Chang et al.
LEUKEMIA RESEARCH (2004)
Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation
JR Passweg et al.
LEUKEMIA (2004)
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia
HR Salih et al.
BLOOD (2003)
Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia
RT Costello et al.
BLOOD (2002)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
The biology of human natural killer-cell subsets
MA Cooper et al.
TRENDS IN IMMUNOLOGY (2001)
分享论文
